NASDAQ · ZJYL
JIN MEDICAL INTERNATIONAL financials
$1.88−3.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 |
|---|---|---|---|
| Revenue | $20.7M | $23.5M | $19.8M |
| Gross profit | $6.0M | $9.5M | $6.8M |
| Gross margin | 29.2% | 40.4% | 34.2% |
| Operating income | $608.2K | $3.6M | $2.9M |
| Net income | $1.2M | $3.7M | $2.9M |
| Net margin | 5.8% | 15.6% | 14.5% |
| Diluted EPS | $0.20 | $0.40 | $0.40 |
| EBITDA | $851.6K | $3.9M | $3.1M |
| Operating cash flow | $2.9M | -$1.2M | $3.1M |
| Free cash flow | -$3.7M | -$1.4M | $3.0M |
| Diluted shares | 7.8M | 7.8M | 7.3M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|
| Cash & equivalents | $7.5M | $8.1M | $6.9M |
| Short-term investments | $22.2M | $18.6M | $9.8M |
| Total debt | $18.8M | $11.3M | $4.1M |
| Total assets | $53.4M | $45.8M | $32.9M |
| Total liabilities | $23.8M | $17.2M | $8.9M |
| Shareholders' equity | $29.6M | $28.6M | $24.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology